Regulatory Requirements (Details) (USD $)	3 Months Ended														12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013		Jun. 30, 2013	Mar. 31, 2013		Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Regulatory Assets [Line Items]
Statutory-basis capital and suprluse of health plan subsidiaries	$ 138,600,000						$ 143,800,000								$ 138,600,000	$ 143,800,000
Statutory-basis net income of health plan subsidiaries															(158,000)	44,000	4,300,000
GAAP net income	19,800,000	66,800,000	[1]	33,500,000	50,100,000	[2]	6,000,000	[3],[4]	18,000,000	[5]	124,600,000	[6]	(26,600,000)	[7]	170,126,000	122,063,000	72,120,000
Statutory capital and surplus, regulatory requirements	453,000,000														453,000,000
Capital and surplus unavailable for payment of dividends	453,000,000														453,000,000
Restricted net assets	126,100,000														126,100,000
Subsidiaries [Member] | Department of Managed Health Care [Member]
Regulatory Assets [Line Items]
GAAP equity	1,200,000,000						1,200,000,000								1,200,000,000	1,200,000,000
GAAP net income															$ 140,700,000	$ 122,100,000	$ 181,100,000

[1] Includes $32.1 million of Medicaid premium revenue as a result of Medicaid/Medi-Cal retroactive rate adjustments for periods prior to 2013.

[2] Includes $42.2 million of Medicaid premium revenue as a result of Medicaid/Medi-Cal retroactive rate adjustments related to 2011 and 2012.

[3] Includes a $2.2 million unfavorable adjustment to the gain on sale of discontinued operation, an $8.2 million expense related to our G&A cost reduction efforts, a $5.0 million expense related to the early termination of a medical management contract and $7.1 million of litigation-related expenses.

[4] Includes $31.5 million of premium revenue as a result of Medicaid/Medi-Cal retroactive rate adjustment related to the third quarter of 2012 and prior periods.

[5] Includes a $2.4 million unfavorable adjustment to the gain on sale of discontinued operation and a $7.2 million expense related to our G&A cost reduction efforts.

[6] Includes $119.4 million gain on sale of discontinued operation related to the sale of our Medicare PDP business to CVS Caremark. Also includes $7.9 million of adverse development related to prior years recorded as part of health care costs, and a $10.8 million expense related to our G&A cost reduction efforts.

[7] Includes $25.0 million of adverse development related to prior periods recorded as part of health care costs, a $9.5 million expense related to our G&A cost reduction efforts and an unfavorable $0.7 million in pretax litigation reserve adjustment. Also includes a $6.5 million insurance reimbursement related to a prior legal settlement.